JPS623800A - Determination of ammonia or atp - Google Patents
Determination of ammonia or atpInfo
- Publication number
- JPS623800A JPS623800A JP14124185A JP14124185A JPS623800A JP S623800 A JPS623800 A JP S623800A JP 14124185 A JP14124185 A JP 14124185A JP 14124185 A JP14124185 A JP 14124185A JP S623800 A JPS623800 A JP S623800A
- Authority
- JP
- Japan
- Prior art keywords
- atp
- ammonia
- kinase
- reaction
- glutamine synthetase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 229910021529 ammonia Inorganic materials 0.000 title claims abstract description 38
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 23
- 102000005396 glutamine synthetase Human genes 0.000 claims abstract description 22
- 108020002326 glutamine synthetase Proteins 0.000 claims abstract description 22
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 16
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 16
- 229960002989 glutamic acid Drugs 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 10
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 6
- 239000011574 phosphorus Substances 0.000 claims abstract description 6
- -1 phosphorus compound Chemical class 0.000 claims abstract description 5
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 239000012085 test solution Substances 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 22
- 239000007788 liquid Substances 0.000 abstract description 6
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 4
- 239000004220 glutamic acid Substances 0.000 abstract description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 3
- 235000013922 glutamic acid Nutrition 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
- 239000001301 oxygen Substances 0.000 description 12
- 235000019270 ammonium chloride Nutrition 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 5
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 4
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 4
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 108020004827 Carbamate kinase Proteins 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 229950006790 adenosine phosphate Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 229940073490 sodium glutamate Drugs 0.000 description 3
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- 101710113083 Carbamoyl-phosphate synthase Proteins 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 239000000852 hydrogen donor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- 229930182822 D-threonine Natural products 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000720950 Gluta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010012029 Guanine Deaminase Proteins 0.000 description 1
- 102000013587 Guanine deaminase Human genes 0.000 description 1
- 108010005440 Guanosine deaminase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006746 NADH Dehydrogenase Human genes 0.000 description 1
- 108010086428 NADH Dehydrogenase Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 101000802478 Sylvirana guentheri Brevinin-2GHa Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 108030006907 Ureidosuccinases Proteins 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 239000007999 glycylglycine buffer Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108010025509 omega-amidase Proteins 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 1
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
- 239000011678 thiamine pyrophosphate Substances 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/008—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions for determining co-enzymes or co-factors, e.g. NAD, ATP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は酵素法によるアンモニアまたはATPの定量法
に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a method for quantifying ammonia or ATP using an enzymatic method.
従来・アンモニアの定量法としては・インドフェノール
法という化学的測定法が主に用いられている。また、酵
素的測定法としては1グルタミン酸脱水素酵素を用いる
方法(例えば特公昭57−21995号参照)が知られ
ている0この方法では、用いられるグルタミン酸脱水素
酵素のアンモニアに対するKm値が大きいため1測定に
多量のグルタミン酸脱水素酵素を必要とする問題を有し
ている。さらに他の酵素的測定法としてはカルバメート
キナーゼを用いる方法(特開昭59−213399号参
照)、またはカルバモイルリン酸合成酵素を用いる方法
(特開昭60−47698号参照)が知られている。Conventionally, a chemical measurement method called the indophenol method has been mainly used to quantify ammonia. Furthermore, as an enzymatic measurement method, a method using 1-glutamic acid dehydrogenase (for example, see Japanese Patent Publication No. 57-21995) is known. The problem is that a large amount of glutamic acid dehydrogenase is required for one measurement. Furthermore, as other enzymatic measurement methods, a method using carbamate kinase (see JP-A-59-213399) or a method using carbamoyl phosphate synthase (see JP-A-60-47698) is known.
前者の方法では用いられるカルバメートキナーゼが一般
的に不安定で、透析などの処理により失活すると報告さ
れている。それ故、還元型グルタチオン、2−メルカプ
トエタノールなどのSH基保護剤の存在下で酵素を精製
あるいは保存する必要がある。ところが、これらのSH
基保護剤を含むカルバメートキナーゼ標品を用いて・被
検液中のアンモニアを酸化酵素−ヘルオキシダーゼー水
素供与体色源体反応系を含む系で定量する場合、SH基
保護剤の存在はペルオキシダーゼ水素供与体の発色系を
阻害するので、正確な測定値が得られず負の誤差を与え
ることになる。後者の方法では用いられるカルバモイル
リン酸合成酵素が動物臓器由来のものしか入手できない
ため、酵素の大量かつ安価な供給という点で問題を有し
ている。It has been reported that the carbamate kinase used in the former method is generally unstable and is inactivated by treatments such as dialysis. Therefore, it is necessary to purify or preserve the enzyme in the presence of an SH group protecting agent such as reduced glutathione or 2-mercaptoethanol. However, these SH
When quantifying ammonia in a test solution using a carbamate kinase preparation containing a group-protecting agent and using a system that includes an oxidase-heroxidase-hydrogen donor chromogen reaction system, the presence of an SH group-protecting agent is due to peroxidase. Since the color development system of the hydrogen donor is inhibited, accurate measurement values cannot be obtained and a negative error is given. Since the carbamoyl phosphate synthase used in the latter method can only be obtained from animal organs, there is a problem in supplying the enzyme in large quantities and at low cost.
また、ATPの定量法としては、従来ダルコー素を作用
させ、生成したNADPHを340nmで測定する方法
〔メソッヅ・オプ・エンザイマティツク・アナリシス、
第7巻、筒346頁(1985))、またはルシフェリ
ンおよびMg2+の存在下でATEにルシフェラーゼを
作用させ、発生する562nmの光強度よりATPを定
量する方法が知られている〔同第7巻、第357頁(1
985))。In addition, as a method for quantifying ATP, there is a conventional method in which darcochloride is applied and the generated NADPH is measured at 340 nm [Methods Op Enzymatic Analysis,
Vol. 7, p. 346 (1985)), or a method is known in which luciferase is allowed to act on ATE in the presence of luciferin and Mg2+, and ATP is quantified from the generated light intensity at 562 nm [Vol. 7, p. 346 (1985)]. Page 357 (1
985)).
しかし前者の方法では、ATE 1分子よりNADPH
1分子しか生成しないため感度が低く1また・後者の方
法ではルシフェリンおよヒルシフェラーゼが高価である
という問題を有している。However, in the former method, more NADPH than one ATE molecule
Since only one molecule is produced, the sensitivity is low, and the latter method has problems in that luciferin and luciferase are expensive.
本発明の目的は1上記現状に鑑み1アンモニアまたはA
TPの高感度で簡便かつ安価な定量法を提供することに
ある。The purpose of the present invention is to: 1. In view of the above-mentioned current situation, 1. ammonia or A.
The object of the present invention is to provide a highly sensitive, simple, and inexpensive method for quantifying TP.
本発明を概説すれば、本発明はアンモニアまたはATP
の定量法に関するものであり、被検液中のアンモニアま
たはATPを定量するに当り、被定量成分ではないもう
一方の物質およびL−グルタミン酸の存在下で被検液に
グルタミン合成酵素を作用させ、生成したADPとキナ
ーゼ基質用リン化合物にキナーゼを作用させて、生成し
たキナーゼ反応生成物を定量することを特徴とする。上
記被定量成分ではないもう一方の物質とは、アンモニア
定量の場合ATPを、またATP定量の場合アンモニア
を表わすものとする。To summarize the present invention, the present invention provides ammonia or ATP.
In quantifying ammonia or ATP in a test solution, glutamine synthetase is allowed to act on the test solution in the presence of L-glutamic acid and another substance that is not the component to be quantified, The method is characterized in that a kinase is made to act on the generated ADP and a phosphorus compound for a kinase substrate, and the generated kinase reaction product is quantified. The other substance that is not the component to be quantified is ATP in the case of ammonia quantification, and ammonia in the case of ATP quantification.
本発明はサイクリング反応を利用した定量法であり高感
度であること1比色定量が可能であう。と、グルタミン
合成酵素が微生物より安価かつ大量に調整可能であるこ
と、とくにマイクロコツカス属およびブレビバクテリウ
ニ属のグルタミン合成酵素は菌体内タンパク質の2〜3
%にまで達し、また非常に安定である、などの特徴を有
しており、臨床検査分野に新規なアンモニアまたはAT
Pの定量法を提供するものである。The present invention is a quantitative method that utilizes a cycling reaction, and is highly sensitive.1 Colorimetric determination is possible. In particular, the glutamine synthetase of Micrococcus spp. and Brevibacterium spp.
% and is extremely stable, making it a new ammonia or AT product in the field of clinical testing.
This provides a method for quantifying P.
本発明に供される被検液としては、アンモニアまたはA
T]’のいずれか一方を含むものであればよく、アンモ
ニアまたはATPを予め含む被検液や、酵素反応により
生成されたアンモニアまたはATPを含む被検液がある
。酵素反応によりアンモニアを生成する反応には、以下
に例示するものがあるが、それらの酵素活性測定、基質
または生成物の定mを行うことが可能である。The test liquid used in the present invention includes ammonia or A
It is sufficient that the test liquid contains either one of T]', and examples thereof include a test liquid that contains ammonia or ATP in advance, and a test liquid that contains ammonia or ATP produced by an enzyme reaction. Examples of reactions that produce ammonia by enzymatic reactions include those listed below, and it is possible to measure their enzyme activity and determine the amount of substrates or products.
1.7スパラギナーゼ(EC!3.5.1.1)L−ア
スパラギン+HIO−+ J、−アスパラギン僧+N
H32、アスパルターゼ(ICO4,3,1,1)L−
アスパラギン酸→ フマール酸十NH。1.7 Sparaginase (EC! 3.5.1.1) L-asparagine + HIO-+ J, -asparagine + N
H32, aspartase (ICO4,3,1,1)L-
Aspartic acid → fumaric acid 1NH.
3、アデニンデアミナーゼ(Mg3.5.4.2)アデ
ニン十HzO→ ヒボキサンチン十NH34、アデノシ
ンデアミナーゼ(to3.5.4.4)アデノシン十H
xO→イノシン十NHs5、アデノシンモノリン酸デア
ミナーゼ(EC3・5・4・6)AMP + Hto
→工MP + ME s6、アデノシンIJ ン酸テ
アミナーゼ(to3.5.4.17)アデノシンリン酸
+H,O→ イノシンリン酸+mHs7、−yミンデヒ
ドaゲナーゼ(KOl、4.99.3)8、アルギニ>
デアミナーゼ(to3.5.3.6)L−アルギニン→
L−シトルリン十NHs9、アミダーゼ(KO3,5,
1,4)モノカルボン酸アミド+J(,0→モノカルボ
ンm+yns10、ω−アミダーゼ(EC3,5,1,
3)2−ケトグルタラミン酸+H,O→ 2−ケトグル
タル酸十NH311、ウレアーゼ(KO3、5、1、5
)尿素十H!O→2 NHz + OO!12、ウレイ
ドスクシナーゼ(B:03.5.1.7)13、グアニ
ンデアミナーゼ(KO3,5,4,3)グアニン+H,
O→キサンチン+NH。3. Adenine deaminase (Mg3.5.4.2) Adenine 10HzO → Hyboxanthin 10NH34, Adenosine deaminase (to3.5.4.4) Adenosine 10H
xO→Inosine 1NHs5, adenosine monophosphate deaminase (EC3/5/4/6) AMP + Hto
→ Engineering MP + ME s6, adenosine IJ acid theaminase (to3.5.4.17) adenosine phosphate + H, O → inosine phosphate + mHs7, -yminedehyde a genease (KOl, 4.99.3) 8, arginine>
Deaminase (to3.5.3.6) L-arginine →
L-citrulline NHs9, amidase (KO3,5,
1,4) Monocarboxylic acid amide + J (,0 → monocarboxylic m + yns10, ω-amidase (EC3,5,1,
3) 2-ketoglutamic acid + H, O → 2-ketoglutaric acid + NH311, urease (KO3, 5, 1, 5
) Urea 10H! O → 2 NHz + OO! 12, ureidosuccinase (B:03.5.1.7) 13, guanine deaminase (KO3,5,4,3) guanine + H,
O → xanthine + NH.
14、グアノシンデアミナーゼ(IO3,5,4,15
)グアノシン+H,O→キサントシン+NH3ニコチン
アミド十H,O→ニコチンm+NHsL−ヒスチジン→
ウロカニン酸十NH。14, Guanosine deaminase (IO3,5,4,15
) Guanosine + H, O → Xanthosine + NH3 Nicotinamide 1 H, O → Nicotine m + NHsL-Histidine →
Urocanic acid 1NH.
また、酵素反応によりATPを生成する反応としては以
下に例示するものがあるが、それらの。In addition, there are the following examples of reactions that generate ATP by enzymatic reactions.
酵素活性測定・基質または生成物の定量を行うことが可
能である。It is possible to measure enzyme activity and quantify substrates or products.
L−チロシン+ATP −)−tRNA2.7セチルー
OoAシンセターゼ(EO6,2,1,1)AMP−1
−PPi+アセチル−0oAコ ATP+酢酸+OoA
SHAMP+ビロリン酸+AMP 2 ATP+デアミ
ド−NAD+NH。L-Tyrosine+ATP-)-tRNA2.7 Cetyl-OoA Synthetase (EO6,2,1,1)AMP-1
-PPi+acetyl-0oA ATP+acetic acid+OoA
SHAMP + birophosphoric acid + AMP 2 ATP + deamide-NAD + NH.
以上これらは例示であり、何ら本発明の対象を限定する
ものではない。These are merely examples and do not limit the scope of the present invention in any way.
次に、本発明に用いられるグルタミン合成酵素は各種高
等動物の脳や肝臓、マメの種子、大腸菌その他の微生物
に存在するが、大社かつ安価に供給できるという点でマ
イクロコツカス属およびブレビバクテリウム属より選ば
れたグルタミン合成酵素生産菌より取得される酵素(こ
のグルタミン合成酵素については特開昭57−3359
4号参照)を使用するのが有利である0まず・本発明に
使用されるグルタミン合成酵素の各性質を示す。Next, although the glutamine synthetase used in the present invention is present in the brains and livers of various higher animals, bean seeds, Escherichia coli, and other microorganisms, Micrococcus spp. and Brevibacterium spp. Enzymes obtained from glutamine synthetase-producing bacteria selected from the genus
First, the properties of the glutamine synthetase used in the present invention will be shown.
グルタミン合成酵素の酵素化学的および理化学的性質
(1)作 用:
本酵素は下式のようにL−グルタミン酸とアンモニアよ
り、ATPの化学エネルギーを利用してグルタミンを合
成する反応を触媒する。Enzyme-chemical and physicochemical properties of glutamine synthetase (1) Action: This enzyme catalyzes the reaction of synthesizing glutamine from L-glutamic acid and ammonia using the chemical energy of ATP, as shown in the following formula.
L−グルタミン酸+アンモニア+ATP →L−グル
タミン+ADP+無機リン酸
(2)基質特異性ニ
アミノ基受容体としては、本酵素はL−グルタミン酸に
極めて高い特異性を示す。塩化アンモニウムの代りにヒ
ドロキシルアミンを用いた場合にも、約30%の活性が
認められた。L-glutamic acid + ammonia + ATP → L-glutamine + ADP + inorganic phosphate (2) Substrate specificity As a niamin group receptor, this enzyme shows extremely high specificity for L-glutamic acid. Approximately 30% activity was also observed when hydroxylamine was used instead of ammonium chloride.
(J至適pHおよびpH安定性:
本酵素の至適pHは7.0〜8.0である。また・本酵
素を50’Cにおいて、それぞれのpklで10分間処
理したとき、pH6,0〜9.0の範囲で安定であるC
[4)至適温度および熱安定性:
本酵素の至適温度は50°C付近にあり、pa7.0に
おいて1それぞれの温度で10分間処理したとき50°
Cまで安定である。(J optimal pH and pH stability: The optimal pH of this enzyme is 7.0 to 8.0. Also, when this enzyme was treated with each pkl at 50'C for 10 minutes, the pH was 6.0 to 8.0. C that is stable in the range of ~9.0
[4) Optimal temperature and thermostability: The optimal temperature of this enzyme is around 50°C, and when treated at each temperature for 10 minutes at pa 7.0, the temperature of 50°C
It is stable up to C.
(ω分子社:
本酵素の分子量は沈降平衡法により、偏比容を0475
と仮定したときに約50万である。(ω Molecule Company: The molecular weight of this enzyme was determined by the sedimentation equilibrium method, and the partial specific volume was determined to be 0475.
Assuming that, it is approximately 500,000.
また、5DS−ポリアクリルアミドゲル電気泳動法では
約6万〜6,5万であることから、本酵素は同一のサブ
ユニット8個からなる8量体である。Moreover, since the 5DS-polyacrylamide gel electrophoresis method shows that the amount is approximately 60,000 to 65,000, this enzyme is an octamer consisting of eight identical subunits.
(6)阻 害:
各種代謝産物による百害を検討したところ・アミノ酸類
ではグリシン、L−トリプトファン、D−スレオニン等
で若干の医書が見られる程度であるが、ヌクレオチド、
ヌクレオシド類による阻害は大きく、アデノシン、 A
MP。(6) Inhibition: After examining the damage caused by various metabolites, there are only a few medical records for amino acids such as glycine, L-tryptophan, and D-threonine, but for nucleotides,
Inhibition by nucleosides is large; adenosine, A
M.P.
ADPなどによって活性は強く■害される。Its activity is strongly impaired by ADP and the like.
(′r)金属イオンの影響:
酵素反応には金属イオンとしてMg 1+を要求しSM
n”十でも34%の活性がある〇(8) Km値:
各、基質に対するKm値を求めたところ、L−グルタミ
ン酸に対して7.9 x 10−”M%塩化アンモニウ
ムに対して5.0 x 10−”M、 ATPに対して
1.2 X 10−’Mであった。('r) Effect of metal ions: Enzyme reactions require Mg 1+ as metal ions, and SM
34% activity even with n"0 (8) Km value: When the Km value for each substrate was determined, it was 7.9 x 10-" for L-glutamic acid and 5.9 for M% ammonium chloride. 0 x 10-'M and 1.2 x 10-'M for ATP.
(9)酵素活性測定法: 酵素活性の測定は次のようにして求めた。(9) Enzyme activity measurement method: Enzyme activity was measured as follows.
soomMグルタミン酸ナトリツナトリウム溶液0mi
x250mM塩化アンモニウム溶液0.1ffiA!、
75mM ATP溶液0.1 ml s 300 mM
Mg01g溶液0.1尼、1Mイミダゾール−塩酸緩
裡液(pH7,0)Q、 l ml 、水0.4 rn
lおよび適当に希釈した酵素液Q、 l mi 、反応
液fl 1. Oratで37°C,10分間反応させ
、生成する無機リン酸をフイスヶーサバロウの方法で測
定する方法、および生成するグルタミンをペーパークロ
マトダラフィーで分離し、ニンヒドリン発色法で測定す
る方法により求めた◇グルタミン合成活性の1単位は上
記反応系で1分間に1μMの無機リン酸あるいはグルタ
ミンを生成する酵素量として表示した。soomM sodium glutamate solution 0mi
x250mM ammonium chloride solution 0.1ffiA! ,
75mM ATP solution 0.1ml s 300mM
Mg01g solution 0.1ml, 1M imidazole-hydrochloric acid solution (pH 7,0) Q, lml, water 0.4rn
l and appropriately diluted enzyme solution Q, l mi , reaction liquid fl 1. The reaction was carried out at 37°C for 10 minutes in Orat, and the produced inorganic phosphoric acid was measured using the method of Fuisuka-Sabarou, and the produced glutamine was separated using paper chromatography and measured using the ninhydrin color method. One unit of the determined ◇glutamine synthesis activity was expressed as the amount of enzyme that produces 1 μM of inorganic phosphoric acid or glutamine per minute in the above reaction system.
なお、グルタミン合成酵素の製造方法については特開昭
57−33594号に記載されている。The method for producing glutamine synthetase is described in JP-A-57-33594.
アンモニアおよびATPの定量法
本発明者らは、被検液中のアンモニアまたはATPの定
量方法について鋭意検討を重ねた結果・グルタミン合成
酵素を用いることにより高感度で簡便かつ安価なアンモ
ニアまたはATPの定量法を見出した。被検液中のアン
モニアはL−グルタミン酸とATPの存在下、グルタミ
ン合成酵素の作用により、L−グルタミン、ADPおよ
び無機リン酸を生成し、また被検液中のATPはL−ダ
ルタミン酸とアンモニアの存在下、本酵素作用により1
L−グルタミン、ADPおよび無機リン%を生成する。Quantification method of ammonia and ATP The present inventors have conducted extensive studies on a method for quantifying ammonia or ATP in a test solution. ・The quantification of ammonia or ATP is highly sensitive, simple, and inexpensive by using glutamine synthetase. I found the law. In the presence of L-glutamic acid and ATP, ammonia in the test solution produces L-glutamine, ADP, and inorganic phosphate by the action of glutamine synthetase, and ATP in the test solution produces L-daltamic acid and ammonia. 1 by the action of this enzyme in the presence of
Produces L-glutamine, ADP and % inorganic phosphorus.
酵素反応により生成したADPにキナーゼ基質用リン化
合物の存在下、キナーゼを作用させるとキナーゼ反応生
成物とATPが生成され、サイクリング反応が進行しA
TPが増幅される。この反応の一例としてピルビン酸キ
ナーゼによるADPとホスホエノールピルビン酸からA
TPとピルビン酸を生成する反応が挙げられる。生成し
たピルビン酸の定量には公知の方法を用いることができ
る。例えばピルビン酸にNADHと乳酸脱水素酵素を作
用させ、NADHの340nmの吸光度の減少より定量
するが、またはピルビン酸オキシダーゼを作用させ消費
される酸素を酸素電極で測定するか、生成する過酸化水
素をペルオキシダーゼ系による呈色反応、例えば4−ア
ミノアンチピリン−フェノール−ペルオキシダーゼ法を
用いた場合500nmで定量することかできる。When a kinase is allowed to act on ADP produced by the enzymatic reaction in the presence of a phosphorus compound for the kinase substrate, a kinase reaction product and ATP are produced, and the cycling reaction progresses.
TP is amplified. An example of this reaction is ADP and phosphoenolpyruvate by pyruvate kinase.
An example is a reaction that produces TP and pyruvic acid. A known method can be used to quantify the produced pyruvic acid. For example, by reacting pyruvate with NADH and lactate dehydrogenase, it is determined by the decrease in absorbance of NADH at 340 nm, or by reacting pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode, or by reacting with pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode, or by reacting with pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode, or by reacting with pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode, or by reacting with pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode, or by reacting with pyruvate oxidase and measuring the consumed oxygen with an oxygen electrode. can be quantified at 500 nm using a color reaction using a peroxidase system, for example, the 4-aminoantipyrine-phenol-peroxidase method.
反応に用いられる緩衝液は特に限定されず、リン酸緩衝
液、イミダゾール緩衝液、トリス緩衝液、グリシルグリ
シン緩衝液などが好適であり・pH6〜9S好ましくは
pH7の緩衝液が用pbられるOグルタミン合成酵素は
通常0.2〜2Q単位、好ましくは1〜5単位・キナー
ゼ・例えハヒルビン増キナーゼは、1〜1Q0単位、好
ましくは5単位以上用いられる。また・L−グルタミン
酸濃度は1〜5QmM、好ましくは5〜l QmMs
ATPやキナーゼ基質用リン化合物1例えばホスホエノ
ールピルビン酸およびNADHは少なくとも被検液中の
アンモニアまたはATPのモル量以上用いればよい。反
応温度は20〜400C1反応時間は1〜20分間で反
応は行なわれる。The buffer used in the reaction is not particularly limited, and phosphate buffer, imidazole buffer, Tris buffer, glycylglycine buffer, etc. are suitable.Buffers with pH 6 to 9S and preferably pH 7 are used. Glutamine synthetase is usually used in an amount of 0.2 to 2 Q units, preferably 1 to 5 units. Kinases such as hahirubin increase kinase are used in amounts of 1 to 1 Q0 units, preferably 5 or more units. Also, L-glutamic acid concentration is 1 to 5 QmM, preferably 5 to 1 QmMs
Phosphorus compounds 1 for ATP and kinase substrates, such as phosphoenolpyruvate and NADH, may be used in an amount at least equal to or greater than the molar amount of ammonia or ATP in the test solution. The reaction temperature is 20 to 400C and the reaction time is 1 to 20 minutes.
以下に本発明を、実施例をもって説明するが、本発明が
以下の実施例の範囲のみに限定されるものではない。The present invention will be explained below with reference to examples, but the present invention is not limited to the scope of the following examples.
実施例 1
アンモニアの定量 (ピルビン酸キナーゼ−乳酸脱水素
酵素反応系)
1 M イミダゾール−塩酸緩衝液(pH,7,0)
0.3m150mML−グルタミン酸ナトリウム
Q、l mi3 Q mM ATE
Q、1mt3QmM
ホスホエノールピルビン酸 011d
7.5 mM NADHQ、1m1
1.5M MgO1x
0.1工!2.7M KOI
0.1m130単位7mb
グルタミン合成酵素(合成活性) 0.11
rLl水
1.3 ml上記混合溶液3.0罰に1.2,3.4お
よび5mMの塩化アンモニウム溶液0.1 miをそれ
ぞれ添加し、37℃で5分間反応した。第1図に示すよ
うに添加した塩化アンモニウム量と340nmの吸光度
の減少量には良好な直線関係が得られた。Example 1 Quantification of ammonia (pyruvate kinase-lactate dehydrogenase reaction system) 1 M imidazole-hydrochloric acid buffer (pH, 7.0)
0.3ml 150mmL-sodium glutamate
Q, l mi3 Q mM ATE
Q, 1mt3QmM
Phosphoenolpyruvate 011d
7.5mM NADHQ, 1ml 1.5M MgO1x
0.1 engineering! 2.7M KOI
0.1m 130 units 7mb
Glutamine synthetase (synthetic activity) 0.11
rLl water
To 1.3 ml of the above mixed solution 0.1 ml of 1.2, 3.4 and 5 mM ammonium chloride solutions were added, respectively, and reacted at 37° C. for 5 minutes. As shown in FIG. 1, a good linear relationship was obtained between the amount of ammonium chloride added and the amount of decrease in absorbance at 340 nm.
実施例 2
反応糸)
1 M イミダゾール−塩酸むQ菌液(pH7,0)
0.3m/150mM L−グルタミン酸ナトリ
ウム Q、 l m113 Q mM A
TP 0.1m
130 mM ホスホエノールピルビン酸0.112
4.6mM 4−7ミノアンチビリン
Q、 l m1420mM フェノール
0.1 rILtl、5 M
MgO1z Q、
1mA2.7M KOI
O,1mA6mM チアミンピロホスフ
ェート 0.1 mAlmM XFA
D 0.1rrl
A30単wmt グルタミン合成酵素(合成活性)、
Q、1mj水
1.4成上記混合溶液3. Onle;に
1,2,3.4および5mMの塩化アンモニウム溶液Q
、 l mlをそれぞれ添加し、37°Cで5分間反応
した。@2図に示すように添加した塩化アンモニウム量
と500nmの吸光度の増加量には良好な直線関係が得
られた〇
実施例 3
ATPの定量
1 M イミダゾール−塩酸緩衝液(pH7,0)
0.3m115QmML−グルタミン酸ナトリウム
0.1 ml 50 mM 塩化アンモニ
ウム Q、 l mi13 Q m
M ホスホエノールピルビン酸 Q、 l
mi7.5mM NADH041m1j
1.5 M Mg011
0.1m12.7M KOI
o、xmt30単V′mt
グルタミン合成酵素(合成活性) o、 1
mi水 1
.3ml上記混合溶液3. Q mlに0.25 、0
.50.0.75およびl、QmMのATP溶液0.1
蛯をそれぞれ添加。Example 2 Reaction thread) 1 M imidazole-hydrochloric acid Q bacterial solution (pH 7.0)
0.3m/150mM Sodium L-glutamate Q, l m113 Q mM A
TP 0.1m
130 mM Phosphoenolpyruvate 0.112
4.6mM 4-7 Minoantivirine
Q, lm1420mM phenol
0.1 rILtl, 5 M
MgO1z Q,
1mA2.7M KOI
O,1mA6mM Thiamine pyrophosphate 0.1 mAlmM XFA
D 0.1rrl
A30 monowmt glutamine synthetase (synthetic activity),
Q, 1mj water
1.4 Mixed solution 3. Onle; 1, 2, 3.4 and 5mM ammonium chloride solution Q
, 1 ml were added, and reacted at 37°C for 5 minutes. @2 As shown in the figure, a good linear relationship was obtained between the amount of ammonium chloride added and the increase in absorbance at 500 nm. Example 3 Quantification of ATP 1 M imidazole-hydrochloric acid buffer (pH 7,0)
0.3ml115QmML-Sodium Glutamate
0.1 ml 50 mM ammonium chloride Q, l mi13 Q m
M Phosphoenolpyruvate Q, l
mi7.5mM NADH041m1j 1.5M Mg011
0.1m12.7M KOI
o, xmt30 single V'mt
Glutamine synthetase (synthetic activity) o, 1
mi water 1
.. 3ml of the above mixed solution 3. Q 0.25 in ml, 0
.. 50.0.75 and l, QmM ATP solution 0.1
Add each elm.
し、37°Cで反応させ、3分後と5分後のNADlK
の減少の差を測定した。第3図に示すようにATPの添
加量とNADHの減少量には良好な直線関係が得られた
。and reacted at 37°C, and NADlK after 3 and 5 minutes.
The difference in decrease was measured. As shown in FIG. 3, a good linear relationship was obtained between the amount of ATP added and the amount of decrease in NADH.
参考例
グルタミン合成酵素とグルタミン酸脱水素酵素を用いて
アンモニアを定量する場合の反応速度の比較
本発明で使用されるグルタミン合成酵素と酵母由来の従
来のグルタミン酸脱水素酵素を用いて、低濃度のアンモ
ニアを定量する場合、どちらか速やかに終点に達するか
比較試験を行なった。グルタミン合成酵素を用いる場合
の混合溶液組成は45単位/rnl(合成活性)のグル
タ・ミン介成酵素溶液Q、 l miを用いる以外は実
施例1と同様で、またグルタミン酸脱水素酵素を用いる
場合の混合溶液組成は300mMト’Jスー塩酸緩衝液
(pH8,0) 1.0m1s 225mM 2−
’r )グルタA/藤溶液0.1 mε、5 mM
NADPH溶液01づ、300mM塩化アンモニウム溶
液Q、 l mt・45単位/ meグルタミン酸脱水
素酵素溶液Q、l mAおよび水1.5 miである0
上記両混合溶液3. Q rnbに0.5゜10および
2. Q mMの塩化アンモニウム溶液50μlをそれ
ぞれ添加し、37°Cで反応させNADHの減少に基づ
<340nmの吸光度を経時的に測定した。第4図に示
すようにグルタミン合成酵素を用いた場合(A)・いず
れのアンモニア濃度でも釣3分間で反応が終了するのに
対し、グルタミン酸脱水素酵素を用いた場合(B)には
、6〜7分経過時でいずれのアンモニア濃度においても
反応は終了していなかった。Reference Example: Comparison of reaction rates when quantifying ammonia using glutamine synthetase and glutamate dehydrogenase. When quantifying, we conducted a comparative test to determine which method reaches the end point more quickly. When using glutamine synthetase, the mixed solution composition is the same as in Example 1 except for using 45 units/rnl (synthetic activity) of glutamine-mediated enzyme solution Q, lmi, and when using glutamate dehydrogenase. The mixed solution composition is 300mM To'J-HCl buffer (pH 8,0) 1.0mls 225mM 2-
'r) Gluta A/Wisteria solution 0.1 mε, 5 mM
NADPH solution 01, 300 mM ammonium chloride solution Q, l mt·45 units/me glutamic acid dehydrogenase solution Q, l mA and water 1.5 mi 0
Both of the above mixed solutions 3. 0.5°10 and 2. to Qrnb. 50 μl of Q mM ammonium chloride solution was added to each, reacted at 37° C., and the absorbance at <340 nm was measured over time based on the decrease in NADH. As shown in Figure 4, when glutamine synthetase is used (A), the reaction is completed in 3 minutes at any ammonia concentration, whereas when glutamate dehydrogenase is used (B), the reaction is completed within 3 minutes. After ~7 minutes had elapsed, the reaction had not been completed at any ammonia concentration.
以上詳細に説明したように、本発明の定量法によればア
ンモニアまたはATPを高感度かつ持具的に定量するこ
とができる。また本発明に用いるグルタミン合成酵素は
微生物より安価に調製することが可能であり臨床検査試
桑として優れた効果を有する。As explained in detail above, according to the quantitative method of the present invention, ammonia or ATP can be quantitatively determined with high sensitivity and in a convenient manner. Furthermore, the glutamine synthetase used in the present invention can be prepared at a lower cost than microorganisms, and has excellent effects as a clinical test sample.
第1図は本発明の定1号方法の実施例1における検1線
をアンモニア量と340nmの吸光度差との関係で示し
たグラフである。第2図は本発明の定量方法の実施例2
における検量線をアンモニア量と500nmの吸光度差
との関係で示したグラフである。第3図は本発明の定量
方法の実施例3における検量線をATP渣と340nm
の吸光度差との関係で示したグラフである。そして、第
4図は本発明に使用されるグルタミン合成酵素(A)と
従来のグルタミン酸脱水素酵素(B)をそれぞれ用いて
、アンモニアを定量する場合の反応速度を反応時間(分
)と340nmの吸光度差との関係で示したグーラフで
ある。FIG. 1 is a graph showing the relationship between the amount of ammonia and the absorbance difference at 340 nm for the first test line in Example 1 of Method No. 1 of the present invention. Figure 2 shows Example 2 of the quantitative method of the present invention.
2 is a graph showing the calibration curve in terms of the relationship between the amount of ammonia and the difference in absorbance at 500 nm. Figure 3 shows the calibration curve in Example 3 of the quantitative method of the present invention with ATP residue and 340 nm.
It is a graph shown in relation to the absorbance difference. Figure 4 shows the reaction time (minutes) and the reaction rate at 340 nm for quantifying ammonia using the glutamine synthetase (A) used in the present invention and the conventional glutamate dehydrogenase (B). This is a graph shown in relation to the absorbance difference.
Claims (1)
り、被定量成分ではないもう一方の物質およびL−グル
タミン酸の存在下で被検液にグルタミン、合成酵素を作
用させ、生成したADPとキナーゼ基質用リン化合物に
キナーゼを作用させて、生成したキナーゼ反応生成物を
定量することを特徴とするアンモニアまたはATPの定
量法。 2、被検液中に、グルタミン合成酵素、キナーゼおよび
基質用リン化合物を同時に存在させる特許請求の範囲第
1項記載のアンモニアまたはATPの定量法。[Claims] 1. In quantifying ammonia or ATP in a test solution, glutamine and a synthetic enzyme are allowed to act on the test solution in the presence of another substance other than the component to be quantified and L-glutamic acid. A method for quantifying ammonia or ATP, which comprises causing a kinase to act on the generated ADP and a phosphorus compound for a kinase substrate, and quantifying the generated kinase reaction product. 2. The method for quantifying ammonia or ATP according to claim 1, wherein a glutamine synthetase, a kinase, and a phosphorus compound for substrate are present simultaneously in the test solution.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14124185A JPS623800A (en) | 1985-06-27 | 1985-06-27 | Determination of ammonia or atp |
| DE19863621448 DE3621448A1 (en) | 1985-06-27 | 1986-06-26 | Method for the determination of ammonia (or ATP) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14124185A JPS623800A (en) | 1985-06-27 | 1985-06-27 | Determination of ammonia or atp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS623800A true JPS623800A (en) | 1987-01-09 |
Family
ID=15287374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14124185A Pending JPS623800A (en) | 1985-06-27 | 1985-06-27 | Determination of ammonia or atp |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS623800A (en) |
| DE (1) | DE3621448A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03293467A (en) * | 1990-04-10 | 1991-12-25 | Toto Ltd | Formation of surface pattern of ceramic product |
| KR100433683B1 (en) * | 2001-06-18 | 2004-05-31 | 한국과학기술연구원 | A microassay method of glutamine synthetase |
| EP3315611A1 (en) | 2016-10-25 | 2018-05-02 | ARKRAY, Inc. | Quantification method for ammonia, quantification reagent kit, test piece, and ammonia quantification device |
| JP2018068278A (en) * | 2016-10-25 | 2018-05-10 | アークレイ株式会社 | Ammonia quantification method, quantification reagent kit, test piece, and ammonia quantification device |
| EP3441478A1 (en) | 2017-08-10 | 2019-02-13 | ARKRAY, Inc. | Improved glutamine synthetase reaction and method for quantifying ammonia utilizing the same |
| CN113075139A (en) * | 2021-03-29 | 2021-07-06 | 迪瑞医疗科技股份有限公司 | Stable double-reagent blood ammonia determination kit |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2834704A1 (en) * | 1978-08-08 | 1980-02-21 | Boehringer Mannheim Gmbh | METHOD FOR THE QUANTITATIVE ENZYMATIC DETERMINATION OF ADP |
-
1985
- 1985-06-27 JP JP14124185A patent/JPS623800A/en active Pending
-
1986
- 1986-06-26 DE DE19863621448 patent/DE3621448A1/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03293467A (en) * | 1990-04-10 | 1991-12-25 | Toto Ltd | Formation of surface pattern of ceramic product |
| KR100433683B1 (en) * | 2001-06-18 | 2004-05-31 | 한국과학기술연구원 | A microassay method of glutamine synthetase |
| EP3315611A1 (en) | 2016-10-25 | 2018-05-02 | ARKRAY, Inc. | Quantification method for ammonia, quantification reagent kit, test piece, and ammonia quantification device |
| JP2018068278A (en) * | 2016-10-25 | 2018-05-10 | アークレイ株式会社 | Ammonia quantification method, quantification reagent kit, test piece, and ammonia quantification device |
| US10731200B2 (en) | 2016-10-25 | 2020-08-04 | Arkray, Inc. | Quantification method for ammonia, quantification reagent kit, test piece, and ammonia quantification device |
| EP3441478A1 (en) | 2017-08-10 | 2019-02-13 | ARKRAY, Inc. | Improved glutamine synthetase reaction and method for quantifying ammonia utilizing the same |
| US11162123B2 (en) | 2017-08-10 | 2021-11-02 | Arkray, Inc. | Glutamine synthetase reaction and method for quantifying ammonia utilizing the same |
| CN113075139A (en) * | 2021-03-29 | 2021-07-06 | 迪瑞医疗科技股份有限公司 | Stable double-reagent blood ammonia determination kit |
| CN113075139B (en) * | 2021-03-29 | 2022-10-11 | 迪瑞医疗科技股份有限公司 | Stable double-reagent blood ammonia determination kit |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3621448A1 (en) | 1987-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shapiro et al. | [130] Glutamine synthetase (Escherichia coli) | |
| EP0034213B1 (en) | A stabilized aqueous coenzyme solution for use in a clinical assay, a method of stabilizing a labile coenzyme in an aqueous clinical assay solution and a kit for use in said clinical assay | |
| US4923796A (en) | Method for the quantitative enzymatic determination of ADP | |
| US5780256A (en) | Method and composition for quantitative determination of ammonia, α-amino acid, or α-keto acid | |
| JPS623800A (en) | Determination of ammonia or atp | |
| JPS62142272A (en) | Quantitative determination of ammonia or atp | |
| EP3441478B1 (en) | Method for quantifying ammonia using an improved glutamine synthetase reaction | |
| JPS60203190A (en) | 1-methylhydantoinase, its production and creatinie measuringmethod and reagent | |
| USRE27524E (en) | Enzymatic determination of nitrogen- containing compounds and enzymes reactive therewith | |
| EP0207493A2 (en) | Method of terminating isocitrate dehydrogenase reaction | |
| Bootsma et al. | Determination of serum 5-nucleotidase by meand of a NADH-linked reaction | |
| JPH0675515B2 (en) | Method for quantifying biological substances using ammonia as reaction product | |
| Deuel et al. | Bacillus subtilis Glutamine Synthetase: DEPENDENCE OF γ-GLUTAMYLTRANSFERASE ACTIVITY ON IONIC STRENGTH AND SPECIFIC MONOVALENT CATIONS | |
| EP0721986A2 (en) | Creatine kinase reagent | |
| US3485723A (en) | Enzymatic determination of nitrogen-containing compounds and enzymes reactive therewith | |
| JP4127767B2 (en) | Measuring reagent using enzyme cycling that can be stored in liquid form | |
| US6696266B1 (en) | Method for assaying ammonia using an NAD-based cycling reaction system | |
| JPH0773517B2 (en) | Method for quantifying creatine kinase | |
| JPH0412119B2 (en) | ||
| JPS5931700A (en) | Determination of organism substance producing ammonia as reaction product | |
| JPH0889292A (en) | Mehtod for stabilizing xanthine dehydrogenase | |
| Makarewicz et al. | AMP-aminohydrolase of human skeletal muscle. The effect of temperature on catalytic functions | |
| CN117805044A (en) | Blood ammonia measuring method | |
| JPH0773514B2 (en) | Ammonia determination method | |
| US20070048813A1 (en) | Agent for assaying analyte of patient by enzyme |